140 related articles for article (PubMed ID: 37604745)
1. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O; Carthon B; Nazha B; Bilen MA
Oncologist; 2021 Nov; 26(11):956-964. PubMed ID: 34096667
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Ozaki K; Hatakeyama S; Narita S; Hata K; Yanagisawa T; Tanaka T; Togashi K; Hamaya T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Kimura T; Habuchi T; Ohyama C
World J Urol; 2023 Jan; 41(1):67-75. PubMed ID: 36520204
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G
Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225
[TBL] [Abstract][Full Text] [Related]
9. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Habuchi T
Int J Clin Oncol; 2022 Sep; 27(9):1477-1486. PubMed ID: 35748967
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.
Muto Y; Narita S; Hatakeyama S; Maita S; Chiba S; Kubo K; Aoyama Y; Ito R; Takahashi Y; Takahashi S; Nakamura K; Honma N; Sato H; Koizumi A; Igarashi R; Okane K; Ishida T; Horikawa Y; Kumazawa T; Akihama S; Shimoda J; Suzuki T; Ohyama C; Habuchi T
Med Oncol; 2021 Mar; 38(4):37. PubMed ID: 33713196
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.
Briones J; Khan M; Sidhu AK; Zhang L; Smoragiewicz M; Emmenegger U
Front Oncol; 2021; 11():658331. PubMed ID: 34026638
[TBL] [Abstract][Full Text] [Related]
17. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Tsaur I; Heidegger I; Bektic J; Kafka M; van den Bergh RCN; Hunting JCB; Thomas A; Brandt MP; Höfner T; Debedde E; Thibault C; Ermacora P; Zattoni F; Foti S; Kretschmer A; Ploussard G; Rodler S; von Amsberg G; Tilki D; Surcel C; Rosenzweig B; Gadot M; Gandaglia G; Dotzauer R;
Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
[TBL] [Abstract][Full Text] [Related]
20. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
